The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
To evaluate the safety and effectiveness of laparoscopic gastrectomy (LG) following neoadjuvant immunochemotherapy (nICT)
Locally Advanced Gastric Cancer
DRUG: immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab
pathological complete response, pathological complete response (pCR), 4 months
major pathological response, major pathological response#MPR, 4 months
comparing the radiological response, pathological response rate, perioperative outcomes, and early recurrence between the two groups.